autoimmune (NZBxNZW)F1 mice.' PLOS ONE. vol.4, no.12, 2009, page E8474, XP002592731, US-A1- 2011123440, US-B1- 6716974, DWYER MARY A ET AL: "Expression and characterization of a DNase I-Fc fusion enzyme", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 274, no.

14, 2 April 1999 (1999-04-02), pages 9738-9743, XP002697473, ISSN: 0021-9258, MACANOVIC M ET AL: "The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, WILEY-BLACKWELL PUBLISHING LTD, GB, vol.106, no.2, 1 November 1996 (1996-11-01), pages 243-242, XP002697474, ISSN: 0009-9104, SONDERMANN P ET AL: "The 3.2-ANG crystal structure of the human IgG1 Fc fragment-FcgammaRIII complex", NATURE, NATURE PUBLISHING GROUP, UNITED KINGDOM, vol.

406, no.6793, 20 July 2000 (2000-07-20), pages 267-273, XP002343993, ISSN: 0028-0836, DOI: 10.1038/35018508, JEFFERIS R ET AL: "Interaction sites on human IgG-Fc for FcgammaR: Current models", IMMUNOLOGY LETTERS, ELSEVIER BV, NL, vol.82, no.1-2, 3 June 2002 (2002-06-03) , pages 57-65, XP002337953, ISSN: 0165-2478, DOI: 10.1016/S0165-2478(02)00019-6, US-A1- 2011081345

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/